Thalidomide and its analogues have distinct and opposing effects on TNF-α and TNFR2 during co-stimulation of both CD4+ and CD8+ T cells

Clinical and Experimental Immunology

Volumn 130, Issue 1, 2002, Pages 75-84

  Marriott, J B ^a   Clarke, I A ^a   Dredge, K ^a   Muller, G ^b   Stirling, D ^b   Dalgleish, A G ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b CELGENE CORPORATION   (United States)

Author keywords

Co stimulation; Immunomodulation; T lymphocyte; Thalidomide; TNF

Indexed keywords

3 (4 AMINO 1,3 DIHYDRO 1,3 DIOXO 2H ISOINDOL 2 YL)GLUTARIMIDE; CC 3052; CD69 ANTIGEN; IMMUNOMODULATING AGENT; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR ALPHA; LENALIDOMIDE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER; CELL MEMBRANE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HUMAN CELL; IMMUNOMODULATION; MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; T LYMPHOCYTE ACTIVATION;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD3; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INFLAMMATION; LIPOPOLYSACCHARIDES; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; NEOPLASMS; PHOSPHODIESTERASE INHIBITORS; RECEPTORS, INTERLEUKIN-2; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; SIGNAL TRANSDUCTION; SOLUBILITY; THALIDOMIDE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036381106     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2002.01954.x     Document Type: Article

References (37)

1. Marriott JB, Muller G, Dalgleish AG. Thalidomide as an emerging immunotherapeutic agent. Immunol Today 1999; 583:538-40.
2. Raje N, Anderson K. Thalidomide - a revival story. N Engl J Med 1999; 341:1606-9.
3. Hales B. Thalidomide on the comeback trail. Nat Med 1999; 5:489-90.
4. Schuler U, Ehninger G. Thalidomide: rationale for renewed use in immunological disorders. Drug Safety 1995; 12:364.
5. Sampaio EP, Sarno EN, Galilly R et al. Thalidomide selectively inhibits tumour necrosis factor α production by stimulated human monocytes. J Exp Med 1991; 173:699-703.
6. Marriott JB, Westby M, Dalgleish AG. The therapeutic potential of TNF-α inhibitors old and new. Drug Discov Today 1997; 2:273-82.
7. Moller DR, Wysocka M, Greenlee BM et al. Inhibition of IL-12 production by thalidomide. J Immunol 1997; 159:5157-61.
8. + subset. J Exp Med 1998; 187:1885-92.
9. Jacobson JM, Greenspan JS, Spritzler J et al. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. N Engl J Med 1997; 336:1487-93.
10. Wolkenstein P, Latarjet J, Roujeau JC et al. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 1998; 352:1586-9.
11. Jacobson JM, Spritzler J, Fox L et al. Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection. J Infect Dis 1999; 180:61-7.
12. Oliver SJ, Moreira A, Kaplan G. Immune stimulation in scleroderma patients treated with thalidomide. Clin Immunol 2000; 97:109-20.
13. Haslett PA, Klausner JD, Makonkawkeyoon S et al. Thalidomide stimulates T cell responses and interleukin 12 production in HIV-infected patients. AIDS Res Hum Retroviruses 1999; 15:1169-79.
14. 2, but not that activated by ceramide, lipopolysaccharides, or phorbol ester. J Immunol 2002; 168:2644-51.
15. Muller GW, Corral LG, Shire MG et al. Structural modifications of Thalidomide produce analogs with enhanced tumour necrosis factor inhibitory activity. J Med Chem 1996; 39:3238-40.
16. Corral LG, Muller GW, Moreira AL et al. Selection of novel analogs of thalidomide with enhanced tumour necrosis factor alpha inhibitory activity. Mol Med 1996; 2:506-15.
17. Corral LG, Haslett PA, Muller GW et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-α. J Immunol 1999; 163:380-6.
18. Moreira AL, Corral LG, Ye WG et al. Thalidomide and thalidomide analogs reduce HIV type 1 replication in human macrophages in vitro. AIDS Res Human Retroviruses 1997; 13:857-63.
19. Marriott JB, Westby M, Cookson S et al. CC-3052: a water soluble analog of thalidomide and potent inhibitor of activation-induced TNF-α production. J Immunol 1998; 161:4236-43.
20. Muller GW, Shire MG, Wong LM et al. Thalidomide analogs and PDE4 inhibition. Bioorg Med Chem Lett 1998; 8:2669-74.
21. Muller GW, Chen R, Huang SY et al. Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production. Bioorg Med Chem Lett 1999; 9:1625-30.
22. + neutrophil apoptosis in vitro. Clin Exp Immunol 2000; 121:472-9.
23. La Maestra L, Zaninoni A, Marriott JB et al. The thalidomide analogue CC-3052 inhibits HIV-1 and tumour necrosis factor-alpha (TNF-alpha) expression in acutely and chronically infected cells in vitro. Clin Exp Immunol 2000; 119:123-9.
24. Hideshima T, Chauhan D, Shima Y. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000; 96:2943-50.
25. Singhal S, Mehta J, Desikan R et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341:1565-71.
26. Juliusson G, Celsing F, Turesson I. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. Br J Haematol 2000; 109:89-96.
27. Zomas A, Anagnostopoulos N, Dimopoulos MA. Successful treatment of multiple myeloma relapsing after high-dose therapy and autologous transplantation with thalidomide as a single agent. Bone Marrow Transplant 2000; 25:1319-20.
28. Eisen T, Boshoff C, Mak I et al. Continuous low dose thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer 2000; 82:812-7.
29. Fine HA, Figg WD, Jaeckle K et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 2000; 18:708-15.
30. Patt YZ, Hassan MM, Lozano RD et al. Durable clinical response of refractory hepatocellular carcinoma to orally administered thalidomide. Am J Clin Oncol 2000; 23:319-21.
31. Gutheil J, Finucane D. Thalidomide therapy in refractory solid tumour patients. Br J Haematol 2000; 110:754.
32. Marriott JB, Muller GW, Stirling D, Dalgleish AG. Immunotherapeutic and anti-tumour potential of thalidomide analogues. Exp Opin Biol Ther 2001; 1:675-82.
33. Dredge K, Marriott JB, Todryk SM et al. Protective antitumor immunity induced by a co-stimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity J Immunol 2002; 168:4914-9.
34. Tartaglia LA, Goeddel DV, Reynolds C et al. Stimulation of human T-cell proliferation by specific activation of the 75-kDa tumour necrosis factor receptor. J Immunol 1993; 151:4637-41.
35. Lin R-H, Hwang Y-W, Yang B-C, Lin C-S. TNF receptor-2-triggered apoptosis is associated with the down regulation of Bcl-xl on activated T cells and can be prevented by CD28 co-stimulation. J Immunol 1997; 158:598-603.
36. Gori A, Rossi MC, Trabattoni D et al. Tumor necrosis factor-α increased production during thalidomide treatment in patients with tuberculosis and human immunodeficiency virus coinfection. J Infect Dis 2000; 182:639-40.
37. Wohl DA, Aweeka FT, Schmitz J et al. Safety, tolerability, and pharmacokinetic effects of thalidomide in patients infected with human immunodeficiency virus: AIDS Clinical Trials Group 267. J Infect Dis 2002; 185:1359-63.